In December 2019, an outbreak of a new type of acute respiratory disease (pneumonia) was reported in central China, and the number of people infected with it increased rapidly. Doctors named this disease COVID–19 and identified its origin as a virus called SARS–COV–2. So far, no effective drug has been produced that can be used to treat this disease with certainty, but some drugs have been identified and introduced that have shown a significant effect on the recovery of patients. The aim of this study is to evaluate and analyze the drugs that have been used to treat Covid–19 patients so that the drugs that have the greatest effect on the recovery of patients can be identified and introduced. The drugs lopinavir and ritonavir, in combination with complementary drugs such as interferon alpha, have been effective in reducing the load capacity of the Betacoronaviruses family. The drugs hydroxychloroquine and chloroquine have been effective in limiting the replication of COVID–19 in laboratory conditions. The antiviral drug amantadine reduces the replication capacity of the virus. Remdesivir can prevent lung damage caused by coronavirus infection in humans. In the case of favipiravir, studies have shown a recovery rate of 91.43%, indicating a very high effectiveness of this drug. Favipiravir and remdesivir have shown significant effectiveness. The drugs lopinavir and ritonavir, used in combination with interferon alpha, as well as hydroxychloroquine and chloroquine, have shown low effectiveness.